INTRODUCTION {#sec1-1}
============

Laparoscopic cholecystectomy is currently considered the treatment of choice for most patients with acute cholecystitis.\[[@ref1][@ref2][@ref3]\] In high surgical risk patients such as having an advanced malignant tumor or other severe organ failures, gallbladder drainage is considered an alternative method. Percutaneous transhepatic gallbladder drainage (PTGBD) is the gold standard method for gallbladder drainage.\[[@ref4][@ref5]\] However, PTGBD has also several potential complications, including bleeding, decreasing of patient\'s quality of life due to external drainage, and it is unsuitable for patients who have massive ascites or dementia, which may lead to the possibility of tube dislodgement.\[[@ref6]\]

For these conditions, percutaneous transhepatic gallbladder aspiration and endoscopic transpapillary gallbladder drainage with either nasobiliary drainage tube or stent placement are usually performed as an alternative.\[[@ref7]\]

Recently, endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) has emerged for acute cholecystitis.\[[@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15]\] However, adverse events can occur after the EUS-GBD procedure such as stent occlusion and stent migration which may be fatal. Moreover, the long-term outcome of EUS-GBD is still unclear.

The aim of this study was to evaluate long-term outcomes of EUS-GBD in high-risk patients with acute cholecystitis who are not candidates for surgical intervention. Also, safety and efficacy of fully covered self-expandable metal stent (FCSEMS) with inside pigtail plastic stent were assessed.

PATIENTS AND METHODS {#sec1-2}
====================

Patients {#sec2-1}
--------

In this study, consecutive patients who underwent EUS-GBD for acute cholecystitis between February 2014 and September 2016 were retrospectively included. During this period, PTGBD was done in six patients and cholecystectomy was performed in 62 patients. In our hospital, the indications of EUS-GBD in acute cholecystitis were the following: having an advanced malignant tumor, severe organ failures, or risk of self removal of tube in case of percutaneous drainage.

The patients were continuously followed up by blood tests and imaging modalities (abdominal ultrasonography and computed tomography (CT) for detection of stability of the stent and patency of cystic duct in patients in whom stent was removed) every 2--4 months. Patients provided their written, informed consent for all procedures associated with the study. This study was approved by the Hospital\'s Institutional Review Board (IRB) for human research.

Technical tips of endoscopic ultrasound-guided gallbladder drainage {#sec2-2}
-------------------------------------------------------------------

All patients were given antibiotics prior to the procedure. Also, all patients performed abdominal CT the day after EUS-GBD to confirm the stable position of the stent as stent migration may be fatal.

First, an echoendoscope (GF-UGT260; Olympus Optical, Tokyo, Japan) was introduced into the stomach or duodenum. The echoendoscope was manipulated until an appropriate puncture route, free from interposing vessels, using color Doppler was identified. The puncture site was selected as the region where the distance between the gastrointestinal tract and the gallbladder was smallest (1 cm or less). When both the stomach and duodenum provided equally good access, the duodenum was preferred because it was easier to maintain the scope position at the duodenum than at the stomach.

While approaching the gallbladder from the stomach, body of the gallbladder was the preferred target as it can be easily accessed from the gastric antrum. On the other hand, in approaching the gallbladder from the duodenum, the neck of the gallbladder (which is the part attached to cystic duct) was the ideal target as it can be easily accessed from duodenal bulb. And from the anatomical point of view, for better placement of stent. Puncture directed toward the neck of gallbladder is preferred as this area is less mobile and its movement away from the duodenal wall is less likely.\[[@ref16]\] Then, the neck or body of the gallbladder was punctured with a 19 G fine-needle aspiration (FNA) (Sonotip pro control 19 G; Medi-Globe GmbH, Rosenheim, Germany) under EUS guidance.

Bile juice was aspirated and a small amount of contrast medium was injected. Then, 0.025-inch guidewire (VisiGlide; Olympus Medical Systems, Tokyo, Japan) was then inserted into the gallbladder through the FNA needle. Next, fine gauge balloon catheter (4 mm, REN; KANEKA, Osaka, Japan) was inserted, and the gallbladder and the intestinal wall were dilated. After this procedure, FCSEMS placement (BONA stent, Standard Sci Tech Inc., Seoul, Korea) from the gallbladder to the intestine was performed under EUS and fluoroscopic guidance using intrachannel release technique in which we stabilized EUS scope until the stent was deployed up to 1 cm within the scope. Then, the EUS scope was pulled a little bit after stent delivery system was pushed. Finally, the stent release was performed mainly under the endoscopic view guidance. A double pigtail plastic stent (7Fr, 10 cm, Cook Medical, Bloomington, Indiana, USA) was placed within the metallic stent to prevent stent migration.\[[@ref11]\] In some patients we used 6 cm FCSEMS with 10 cm inside pigtail plastic stent, while in other patients we used 8 cm FCSEMS with 12 cm pigtail plastic stent.

Definitions {#sec2-3}
-----------

The follow-up period was measured from the day of performance of EUS-GBD to the final observation. Procedure time was also measured from echoendoscope insertion to stent placement. Technical success was defined as successful FCSEMS and plastic stent deployment. Functional success was also defined as complete resolution of clinical symptoms, such as abdominal pain and fever, or decreased inflammation or liver enzymes on blood tests.

Recurrence of acute cholecystitis after EUS-GBD was defined based on the characteristic clinical features such as abdominal pain and fever, laboratory data, and imaging studies. Adverse events of EUS-GBD included early adverse events (\<2 weeks) and late adverse events (\>2 weeks) and were defined according to the American Society for Gastrointestinal Endoscopy Lexicon\'s severity grading system.\[[@ref17]\]

The patients had severe underlying diseases such as advanced cholangiocarcinoma, advanced pancreatic adenocarcinoma, severe cerebrovascular diseases (e.g., cerebral infarction, carotid aneurysm), and cardiopulmonary diseases (e.g., congestive heart failure, hypertrophic cardiomyopathy) for which surgery and general anesthesia carried high risk. Also, PTGBD was refused by some patients because of poor performance status and risk of inadvertent tube dislodgement. In addition, few patients had dementia for which PTGBD was inconvenient.

The severity of each patient\'s condition was assessed by American Society of Anesthesiologists physical status (ASA PS) classification.\[[@ref18]\]

Statistical analysis {#sec2-4}
--------------------

Results are given as medians (range) and means (±standard deviation \[SD\]). The patients\' characteristics were compared by Student\'s *t*-test for continuous variables and Fisher\'s exact test for categorical variables. All statistical analyses were performed using Statistical Package for the Social Sciences version 23 (IBM Corp., Armonk, New York, USA) statistical software.

RESULTS {#sec1-3}
=======

Patients\' characteristics {#sec2-5}
--------------------------

Totally, 13 patients (mean age 74.92 years, range 63--90 years; 10 males, 3 females) were enrolled for the study \[[Table 1](#T1){ref-type="table"}\]. Eight patients were ASA class III and five patients were ASA class IV. Also, five patients had advanced malignancy (one patient had renal cell carcinoma with pancreatic metastasis, another patient had pancreatic cancer with liver and lymph node metastasis, another patient had combined pancreatic cancer and cholangiocarcinoma, and two patients had advanced cholangiocarcinoma). On blood examination, the mean white blood cell (WBC) count was 12.09 μl^−1^, and the mean C-reactive protein (CRP) was 12.52 mg/dl. Indication for EUS-GBD was acute cholecystitis (*n* = 13).

###### 

Patients\' characteristics
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Results of endoscopic ultrasound-guided gallbladder drainage {#sec2-6}
------------------------------------------------------------

[Table 2](#T2){ref-type="table"} shows the results of EUS-GBD. EUS-GBD was performed and was technically successful in all patients and functionally successful in 12 patients. The EUS-GBD procedure was performed via the stomach and duodenum in four and nine cases, respectively. The median procedure time was 26.9 min (range 19--42 min). On CT imaging, stent migration was not seen in any patients, and swelling of the gallbladder was resolved. However, pneumoperitoneum was seen in one patient and responded well to conservative treatment.

###### 

Results of EUS-GBD
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Seven days after EUS-GBD, the mean WBC count was 9860 μl^−1^ (range 3660--22340 μl^−1^), and CRP was 5.8 mg/dl (range 0.61--24.39 mg/dl).

Long-term outcomes after endoscopic ultrasound-guided gallbladder drainage {#sec2-7}
--------------------------------------------------------------------------

[Table 3](#T3){ref-type="table"} shows the long-term outcomes after EUS-GBD. The median follow-up time was 240 days (range 14--945 days). Recurrence of cholecystitis based on clinical symptoms, laboratory markers, and imaging studies was observed in one patient (7.7%). Also, during this period, four patients died due to underlying comorbid diseases (advanced malignancy in two, cardiopulmonary diseases in one, and severe pneumonia in one patient). Of those four patients, two patients lived for 6 months after EUS-GBD and the other two patients lived for 1 month. Moreover, distal stent migration was seen by abdominal CT in one patient 2 weeks after EUS-GBD for whom another EUS was done and the stent was removed and was not replaced as there was no recurrence of cholecystitis.

###### 

Long-term outcomes after EUS-GBD
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DISCUSSION {#sec1-4}
==========

The aim of the current study was to evaluate the feasibility and safety of EUS-GBD in patients with acute cholecystitis who are not candidates for cholecystectomy. In high surgical risk patients with acute cholecystitis, gallbladder drainage is considered an alternative treatment. PTGBD is considered the first-line drainage method. However, this drainage method is not indicated for patients who have massive ascites or are on anticoagulant therapy.\[[@ref11]\]

Moreover, PTGBD has several disadvantages such as biliary peritonitis, pneumothorax, and bleeding, which can occur in up to 12% of cases.\[[@ref4]\] Also, patients\' quality of life may be decreased due to external drainage and postprocedural pain, and inadvertent tube dislodgement or migration has been reported in up to 12% of cases.\[[@ref19]\] Furthermore, recurrence of cholecystitis after PTGBD tube removal occurred in 22--47% of cases if surgical treatment was not performed.\[[@ref20][@ref21]\]

On the contrary, EUS-GBD can be performed in patients taking anticoagulant therapy because the gastrointestinal tract is less vascular than the liver and it is associated with improved patients\' quality of life.\[[@ref10][@ref22]\] If EUS-GBD is performed using self-expandable metallic stent (SEMS) or another large diameter metallic stent, compared with a PTGBD tube, a greater drainage effect may be obtained.\[[@ref11]\]

Previous reports about EUS-GBD (including at least five cases and excluding nasobiliary tube only) are summarized in [Table 4](#T4){ref-type="table"}.\[[@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15]\] The reported technical success rate of EUS-GBD ranged from 84.6 to 100%, and the functional success rate ranged from 96 to 100%. The puncture sites were transgastric in 42.2% (57/135) and transduodenal in 57.8% (78/135). The stents used with EUS-GBD were pigtail plastic stents, BONA-AL metallic stents, or AXIOS metallic stents. The most frequent adverse events were pneumoperitoneum (*n* = 4) and stent migration (*n* = 3). Also, recurrence of cholecystitis was seen in previous reports.\[[@ref10][@ref15]\]

###### 

Overview of outcomes of EUS-GBD
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The methods and devices used for EUS-GBD have not yet been standardized. Technical tips for the present technique are divided into two important points: (1) to puncture the gallbladder neck and (2) to use relatively long SEMS and pigtail stents. EUS-GBD has two puncture sites. One is transgastric and the other is transduodenal. If EUS-GBD is performed via transgastric approach, the gallbladder body is normally punctured and this may be associated with increased risk of bile leakage and distal stent migration which may be attributed to the relatively long distance between the gallbladder and the stomach. On the contrary, if it is performed via transduodenal approach, the neck of the gallbladder is punctured. Puncturing of the gallbladder neck is preferred because it is less mobile, making stent migration less likely to occur, and the top of the stent is directed toward gallbladder fundus making it difficult for food or sludge to flow into the common bile duct through the cystic duct.\[[@ref23]\] In addition, the inflamed gallbladder becomes adherent to the duodenal wall, making bile leakage through puncture site less likely to occur.\[[@ref16]\] Most studies did not mention the reason of transduodenal approach vs. transgastric approach. However, Walter *et al*. hypothesized that transduodenal access may result in less tissue reaction after longer stent dwell time, so it was considered the access of choice.\[[@ref15]\] In our study, transduodenal approach with puncturing gallbladder neck was performed in nine patients, while transgastric approach with puncturing gallbladder body was performed in four patients in whom puncturing gallbladder neck was technically difficult. Also, we usually obstruct the cystic duct using a relatively long FCSEMS. Then, a pigtail plastic stent is inserted inside the FCSEMS. This pigtail plastic stent has two important roles: One is to prevent stent migration, and the other is to prevent food flowing into the gallbladder.\[[@ref11]\]

Recently, a novel metallic stent with anchor flanges and flares is available for EUS-GBD, and it may be much better than straight FCSEMS in preventing stent migration.\[[@ref24][@ref25][@ref26]\] However, if this flanged metallic stent is not used, a pigtail plastic stent should be added into the straight metallic stent.\[[@ref27]\] In a systematic review of EUS-GBD, lumen apposing metal stent seemed to have higher efficacy and safety; however, its technical success was lower compared to conventional biliary SEMS (91.5% vs. 98.6%, respectively).\[[@ref28]\]

In the present study, patients were followed after EUS-GBD to assess if clinical symptoms or stent-related adverse events occurred or not to avoid unnecessary interventions. Our findings were comparable with a study done by Choi *et al*., who followed patients after EUS-GBD (median 275 days; range 40--1185 days), and during that follow-up period, 54 patients (96.4%) had no recurrence of cholecystitis.\[[@ref10]\]

Even when stent migration occurs, patients are less likely to have a recurrence of cholecystitis, presumably due to the maturation of cholecystoenteric fistula.\[[@ref10]\] Also, our findings were compared with a study done by Kamata *et al*., who followed patients after EUS-GBD (median 304 days; range 78--1492 days), and during that follow-up period, 11 patients (91.7%) had no recurrence of cholecystitis.\[[@ref29]\]

The study is limited by its single-center retrospective design, small sample size, and the lack of a control group.

CONCLUSION {#sec1-5}
==========

In conclusion, EUS-GBD with a FCSEMS and inside pigtail plastic stent performed by an experienced endosonographer has good long-term outcomes and can be an effective and safe alternative treatment for patients with acute cholecystitis who are unsuitable for surgical interference. However, a prospective, randomized, adequately powered head-to-head comparison of PTGBD and EUS-GBD is required.
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